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Corrigendum: Safety signal dampens reception for mipomersen antisense
Jim Kling
Nat. Biotechnol. 28, 295–297 (2010); published online 8 April 2010; corrected after print 9 July 2010
In the version of this article initially published, some of the oligos in Table 1 are described as phosphorothioate modified. In fact, all antisense 
oligonucleotides are phosphorothioate-modified oligos. In addition, Lucanix, which is not an antisense oligo, has been removed from the table. 
The error has been corrected in the HTML and PDF versions of the article.
Corrigendum: Ab initio reconstruction of cell type–specific transcriptomes in 
mouse reveals the conserved multi-exonic structure of lincRNAs
Mitchell Guttman, Manuel Garber, Joshua Z Levin, Julie Donaghey, James Robinson, Xian Adiconis, Lin Fan, Magdalena J Koziol, 
Andreas Gnirke, Chad Nusbaum, John L Rinn, Eric S Lander & Aviv Regev
Nat. Biotechnol. 28, 503–510 (2010); published online 02 May 2010; corrected after print 9 July 2010
In the version of this article initially published, the fourth sentence in the Online Methods section “RNA extraction and library preparation,” 
that read in part “procedure that combines a random priming step with a shearing step8,9,28 and results in fragments of ~700 bp in size,” should 
have read, “procedure that combines fragmentation of mRNA to a peak size of ~750 nucleotides by heating6 followed by random-primed reverse 
transcription8.” The error has been corrected in the HTML and PDF versions of the article.
Erratum: US biodefense contracts continue to lure biotechs
Catherine Shaffer
Nat. Biotechnol. 28, 187–188 (2010); published online 8 March 2010; corrected after print DD Month 9 July 2010
In the version of this article initially published, in Table 1, the Emergent BioSolutions’ anthrax countermeasures in development listed AV-7909 
as being in phase 2 under a $447.6 million BARDA contract; AV-7909 is in phase 1 and the BARDA contract is for $29.7 million. AIGIV is in 
phase 1/3, not phase 1/2. Finally, a third product was omitted; anthrax monoclonal is in preclinical testing under a $24 million BARDA contract. 
The $447.6 million BARDA contract was for procurement and product enhancements on BioThrax. Also, on p.188, column 2, line 7, the vaccine 
requires five injections, not six as originally stated. The error has been corrected in the HTML and PDF versions of the article.
Erratum: Single base–resolution methylome of the silkworm reveals a sparse 
epigenomic map
Hui Xiang, Jingde Zhu, Quan Chen, Fangyin Dai, Xin Li, Muwang Li, Hongyu Zhang, Guojie Zhang, Dong Li, Yang Dong, Li Zhao,  
Ying Lin, Daojun Cheng, Jian Yu, Jinfeng Sun, Xiaoyu Zhou, Kelong Ma, Yinghua He, Yangxing Zhao, Shicheng Guo, Mingzhi Ye, 
Guangwu Guo, Yingrui Li, Ruiqiang Li, Xiuqing Zhang, Lijia Ma, Karsten Kristiansen, Qiuhong Guo, Jianhao Jiang, Stephan Beck, 
Qingyou Xia, Wen Wang & Jun Wang
Nat. Biotechnol. 28, 516–520 (2010); published online 02 May 2010; corrected after print 9 July 2010
In the version of this article initially published, references 4 and 7 were inadvertently interchanged. The error has been corrected in the HTML 
and PDF versions of the article.
Erratum: Up for grabs
Michael Eisenstein
Nat. Biotechnol. 28, 544–546 (2010); published online 7 June 2010; corrected after print 9 July 2010
In the version of the article originally published, it was stated that the Cohen-Boyer patents generated hundreds of billions of dollars in licensing 
revenue. It should have read hundreds of millions of dollars. The error has been corrected in the HMTL and PDF versions of the article.
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